Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
GWASCAT |
Association analysis identifies 65 new breast cancer risk loci.
|
29059683 |
2017 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
The association for rs11249433 was limited to ER-positive breast cancers (test for heterogeneity P≤8.41 x 10-5).
|
27556229 |
2016 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
To fine-map this locus, we genotyped 92 SNPs in a 900kb region (120,505,799-121,481,132) flanking rs11249433 in 45,276 breast cancer cases and 48,998 controls of European, Asian and African ancestry from 50 studies in the Breast Cancer Association Consortium.
|
27556229 |
2016 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
GWASCAT |
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.
|
25751625 |
2015 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
Our results in two independent data sets suggest that rs11249433, which is located between the NOTCH2 and FCGR1B genes within the 1p11.2 locus, is more strongly associated with risk of breast tumors with low or absent E-cadherin expression, and suggest that evaluation of E-cadherin tumor tissue expression may be useful in clarifying breast cancer risk factor associations.
|
24292867 |
2014 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
Our results in two independent data sets suggest that rs11249433, which is located between the NOTCH2 and FCGR1B genes within the 1p11.2 locus, is more strongly associated with risk of breast tumors with low or absent E-cadherin expression, and suggest that evaluation of E-cadherin tumor tissue expression may be useful in clarifying breast cancer risk factor associations.
|
24292867 |
2014 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
GWASCAT |
Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
|
23535729 |
2013 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
Our findings demonstrated that rs11249433-G allele is a risk-conferring factor for the development of breast cancer, especially in Caucasians.
|
23977314 |
2013 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
In conclusion, this meta-analysis demonstrated that the G allele of 1p11-rs11249433 is a risk factor associated with increased breast cancer susceptibility, but these associations vary in different ethnic populations.
|
23977306 |
2013 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
In conclusion, this meta-analysis demonstrated that the G allele of 1p11-rs11249433 is a risk factor associated with increased breast cancer susceptibility, but these associations vary in different ethnic populations.
|
23977306 |
2013 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
GWASDB |
Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
|
23535729 |
2013 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
Our findings demonstrated that rs11249433-G allele is a risk-conferring factor for the development of breast cancer, especially in Caucasians.
|
23977314 |
2013 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
SNP rs11249433 (1p11.2) was associated with the risk of breast cancer for BRCA2 mutation carriers (HR = 1.09, 95% CI: 1.02-1.17, P-trend = 0.015), but was not associated with breast cancer risk for BRCA1 mutation carriers (HR = 0.97, 95% CI: 0.92-1.02, P-trend = 0.20).
|
21593217 |
2011 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
SNP rs11249433 (1p11.2) was associated with the risk of breast cancer for BRCA2 mutation carriers (HR = 1.09, 95% CI: 1.02-1.17, P-trend = 0.015), but was not associated with breast cancer risk for BRCA1 mutation carriers (HR = 0.97, 95% CI: 0.92-1.02, P-trend = 0.20).
|
21593217 |
2011 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
However, no significant association was observed between rs11249433 and breast cancer risk in this Chinese population (dominant genetic model in combined samples: OR = 1.20, 95% CI = 0.92-1.57).
|
21738711 |
2011 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
However, no significant association was observed between rs11249433 and breast cancer risk in this Chinese population (dominant genetic model in combined samples: OR = 1.20, 95% CI = 0.92-1.57).
|
21738711 |
2011 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
Further studies are needed to investigate possible mechanisms of regulation of NOTCH2 expression by rs11249433 and the role of NOTCH2 splicing forms in breast cancer</span> development.
|
20482849 |
2010 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
Further studies are needed to investigate possible mechanisms of regulation of NOTCH2 expression by rs11249433 and the role of NOTCH2 splicing forms in breast cancer</span> development.
|
20482849 |
2010 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
GWASDB |
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).
|
19330030 |
2009 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
GWASCAT |
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).
|
19330030 |
2009 |
Nasopharyngeal carcinoma
|
|
0.700 |
GeneticVariation
|
GWASDB |
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
|
20512145 |
2010 |
Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
Further, among carriers of rs11249433, the highest risk was seen for E-cadherin low tumors that were ER-positive and of lobular histology.
|
24292867 |
2014 |
Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
In addition, our data indicate that 1p11-rs11249433 polymorphism is involved in BC susceptibility and confer its effect primarily in estrogen receptor-positive and progesterone receptor-positive tumors.
|
23977306 |
2013 |
Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
In addition, we found that rs11249433 polymorphism on 1p11 confer risk, exclusively for ER-positive tumors with per-allele OR of 1.13 (95% CI: 1.08-1.18; P <10(-5)) compared to ER-negative tumors of 1.01 (95% CI: 0.98-1.04; P=0.49).
|
23977314 |
2013 |
Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
Therefore, increased expression of NOTCH2 in carriers of rs11249433 may promote development of ER+ luminal tumors.
|
20482849 |
2010 |